TKG Therapeutics

TKG Therapeutics is a preclinical-stage biotechnology company focused on developing transformative therapies for treatment-resistant solid tumors, with a primary emphasis on pancreatic ductal adenocarcinoma (PDAC). Founded by world-renowned oncology researchers from MD Anderson Cancer Center, the company leverages insights into the KRAS signaling pathway and the tumor microenvironment to identify novel cell-surface targets. Its lead programs focus on targeting Syndecan-1 (SDC1), a protein overexpressed in KRAS-mutant cancers that plays a critical role in nutrient uptake and tumor growth. By inhibiting SDC1, the company's therapies aim to disrupt macropinocytosis, a metabolic process that cancer cells use to survive in nutrient-poor environments. TKG Therapeutics utilizes various modalities, including monoclonal antibodies and antibody-drug conjugates, to target these essential survival mechanisms.